EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world characteristics and survival outcomes of patients with metastatic ALK fusion-positive solid tumors treated with standard-of-care therapies

Shirish M Gadgeel, Otto Fajardo, Fabrice Barlesi, Jeong Eun Kim, Razelle Kurzrock, David M Thomas, Ritika Jagtiani, Johannes Noe, Sven Schwemmers, Christos Nikolaidis iD

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Shirish M Gadgeel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology/Oncology, Henry Ford Cancer Institute/Henry Ford Health, Detroit, MI 48208, United States. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Neoplasms, Oncogene Proteins, Fusion. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: F. Hoffmann-La Roche Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anaplastic lymphoma kinase (ALK) fusions can be found in different solid tumors. This study aims to describe the clinical characteristics and investigate survival outcomes of patients with ALK fusion-positive solid tumors (excluding non-small cell lung cancer [NSCLC]) treated with standard-of-care therapies in a real-world setting. Patients and Methods Data for patients with metastatic solid tumors (excluding NSCLC) who had ≥1 Foundation Medicine comprehensive genomic profiling (CGP) test between January 1, 2011 and September 30, 2023, were obtained from a nationwide (US-based) de-identified multi-tumor clinico-genomic database. Patients with ALK wild-type (ALK-WT) tumors were matched with patients with ALK fusion-positive tumors (4:1 ratio) using pre-specified baseline characteristics. Two models were used to analyze survival outcomes: Model 1 used the CGP report date as the index date; Model 2 used the date of metastatic diagnosis as the index date (including adjustment for immortal time bias).

Results

Overall, 22 and 88 patients were included in the ALK fusion-positive and ALK-WT cohorts, respectively. Co-alterations were rare in the ALK fusion-positive cohort. Median overall survival was consistently lower in patients with ALK fusion-positive tumors compared with patients with ALK-WT tumors, across all analyses (hazard ratios between 1.8 and 2.0).

Conclusion

Data from this study suggest that ALK fusions have a negative prognostic effect in metastatic solid tumors and highlight the need for further investigation of ALK inhibitors in the tumor-agnostic setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anaplastic Lymphoma KinaseNeoplasmsOncogene Proteins, FusionHumansFemaleMaleMiddle AgedAgedAdultNeoplasm MetastasisStandard of CarePrognosis

Stichwörter der Autor:innen

ALKanaplastic lymphoma kinasemetastatic solid tumorsprognostic

Substanzen

Anaplastic Lymphoma KinaseALK protein, humanOncogene Proteins, Fusion

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Hematology/Oncology, Henry Ford Cancer Institute/Henry Ford Health, Detroit, MI 48208, United States.
  • Real World Data Science, Product Development Data Sciences, F. Hoffmann-La Roche Ltd, Basel 4070, Switzerland.
  • Department of Medical Oncology, International Centre for Thoracic Cancers (CICT), Gustave Roussy, Villejuif 94800, France.
  • Faculty of Medicine, Paris Saclay University, Kremlin-Bicêtre 94270, France.
  • Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
  • Precision Oncology Institution, Medical College of Wisconsin (MCW) Cancer Center, Milwaukee, WI 53226, United States.

ORCID-Profile: Christos Nikolaidis

Förderung

  • F. Hoffmann-La Roche Ltd

Zitieren

APA

Gadgeel, S. M., Fajardo, O., Barlesi, F., Eun Kim, J., Kurzrock, R., Thomas, D. M., Jagtiani, R., Noe, J., Schwemmers, S., & Nikolaidis, C. (2025). Real-world characteristics and survival outcomes of patients with metastatic ALK fusion-positive solid tumors treated with standard-of-care therapies. The Oncologist. https://doi.org/10.1093/oncolo/oyaf005

Vancouver

Gadgeel SM, Fajardo O, Barlesi F, Eun Kim J, Kurzrock R, Thomas DM, et al. Real-world characteristics and survival outcomes of patients with metastatic ALK fusion-positive solid tumors treated with standard-of-care therapies. The Oncologist. 2025. doi:10.1093/oncolo/oyaf005

BibTeX
@article{Gadgeel2025,
  author = {Gadgeel, Shirish M and Fajardo, Otto and Barlesi, Fabrice and Eun Kim, Jeong and Kurzrock, Razelle and Thomas, David M and Jagtiani, Ritika and Noe, Johannes and Schwemmers, Sven and Nikolaidis, Christos},
  title = {Real-world characteristics and survival outcomes of patients with metastatic ALK fusion-positive solid tumors treated with standard-of-care therapies},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf005}
}
Kostenlos starten →